603718 海利生物
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-0.3055.33411.3345.2190.840
总资产报酬率 ROA (%)-0.2253.9647.2422.9670.512
投入资产回报率 ROIC (%)-0.2865.05110.7935.0120.787

边际利润分析
销售毛利率 (%)43.73951.39458.96955.76746.837
营业利润率 (%)-7.84222.91923.30916.482-8.339
息税前利润/营业总收入 (%)-6.27624.41746.49319.928-2.716
净利润/营业总收入 (%)-6.20320.77636.89813.149-12.408

收益指标分析
经营活动净收益/利润总额(%)166.113-12.3666.49734.243192.621
价值变动净收益/利润总额(%)-41.652101.0728.61562.819-107.484
营业外收支净额/利润总额(%)0.2321.52146.711-0.1797.428

偿债能力分析
流动比率 (X)1.3941.3492.0731.4561.160
速动比率 (X)1.1611.1021.6221.2430.979
资产负债率 (%)28.23229.13326.63046.46746.148
带息债务/全部投入资本 (%)1.4990.619-2.041-13.039--
股东权益/带息债务 (%)6,238.71215,234.977-4,661.548-731.025-711.071
股东权益/负债合计 (%)263.431251.985282.786117.354128.353
利息保障倍数 (X)-3.96021.34416.8895.735-0.432

营运能力分析
应收账款周转天数 (天)116.181136.280112.32577.6480.000
存货周转天数 (天)222.838381.076420.438302.9780.000